Monopar Therapeutics Inc. MNPR R2K

Healthcare · Biotechnology · United States

https://www.monopartx.com

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Market & Price

Market Cap

$435.71M

Current Price

$65.04

High / Low (52W)

$102.05 / $30.01

Beta

1.50

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$20.59

Price to Book

3.16

P/S

EV/EBITDA

Dividend Yield

Profitability & Returns

ROCE

-12.11%

ROE

-15.86%

ROA

-12.11%

Profit Margin

0.00%

Op Margin

0.00%

EPS (Latest Qtr)

$-0.46

EPS (TTM)

$-1.93

Balance Sheet & Liquidity

Debt/Equity

0.17

Quick Ratio

55.94

Current Ratio

56.05

Debt

$230.43K

Total Assets

$140.72M

Current Assets

$140.46M

Working Capital

$137.73M

Ownership

Promoter Holding

23.23%

Chg in Prom Hold

FII / Inst Holding

93.27%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$298.44M

Total Revenue (TTM)

EBITDA

Free Cash Flow

$-5.38M

Operating Cash Flow

$-10.01M

Shares Outstanding

6.70M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

-10.15%

Revenue (YoY)

Earnings (YoY)

PROS

No notable strengths flagged.

CONS

Earnings shrank at -10.1% CAGR over 5 years.
Trading 36.3% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	MNPR Monopar Therapeutics Inc. R2K	65.04	-	$435.71M	-	-12.11%	-15.86%	-	-10.15%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	0	0	0	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.22M	3.23M	4.09M	6.16M	5.23M
Operating Income	-373.84K	-594.96K	-14.90M	-897.26K	-667.53K	-667.53K	-	-1.41M	-932.11K	-759.45K	-1.14M	-1.46M	-1.65M	-1.89M	-2.09M	-2.46M	-2.46M	-2.76M	-2.41M	-2.53M	-2.33M	-2.07M	-1.72M	-1.79M	-	-	-3.22M	-3.23M	-4.09M	-6.16M	-5.23M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3.22M	-3.23M	-4.09M	-6.16M	-5.23M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.62M	-2.45M	-3.44M	-5.20M	-3.89M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-372.92K	-591.44K	-14.88M	-876.35K	-640.18K	-640.18K	-890.46K	-1.38M	-905.70K	-736.08K	-1.09M	-1.45M	-1.64M	-1.88M	-2.08M	-2.46M	-2.46M	-2.76M	-2.40M	-2.43M	-2.20M	-1.95M	-1.64M	-1.72M	-	-	-2.62M	-2.45M	-3.44M	-5.20M	-3.89M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.37	-	-0.38	-0.35	-0.48	-	-0.46
R&D Expense	133.74K	311.59K	180.68K	457.14K	303.68K	303.68K	-	835.60K	329.29K	219.85K	344.41K	832.50K	1.26M	1.21M	1.48M	1.83M	1.68M	2.08M	1.73M	1.65M	1.59M	1.32M	966.11K	1.13M	984.28K	-	1.64M	1.73M	2.59M	-	3.49M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	0	0	0	0	-	-	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	10.54M	8.83M	16.16M	16.70M
Operating Income	-1.19M	-16.60M	-3.33M	-4.32M	-6.51M	-	-10.54M	-8.83M	-16.16M	-16.70M
EBITDA	-	-	-	-	-	-	-10.54M	-8.83M	-16.16M	-16.70M
Interest Expense	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-10.52M	-8.40M	-15.59M	-13.72M
Tax Provision	-	-	-	-	-	-	-	-	-	-
Net Income	-1.19M	-16.55M	-3.23M	-4.22M	-6.30M	-	-10.52M	-8.40M	-15.59M	-13.72M
Diluted EPS	-	-	-	-	-	-	-4.15	-3.04	-4.11	-1.85
R&D Expense	280.36K	935.32K	1.77M	1.97M	4.07M	6.49M	7.59M	5.60M	13.01M	9.90M

Compounded Sales Growth

5 Years:	-
1 Year:	-

Compounded Profit Growth

5 Years:	-10.15%
1 Year:	-

Stock Price Performance

1 Year:	+104.98%
6 Months:	-26.48%
3 Months:	+18.68%
1 Month:	+29.77%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	2.90M	9.93M	7.32M	13.35M	16.87M	20.52M	13.23M	7.35M	60.29M	140.72M
Current Assets	-	-	-	-	-	-	-	13.17M	7.33M	60.29M	140.46M
Cash & Equivalents	-	2.07M	8.98M	6.89M	13.21M	16.74M	20.30M	8.19M	7.27M	45.82M	61.83M
Inventory	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	64.51K	311.87K	399.55K	724.16K	1.18M	1.58M	3.14M	1.76M	5.25M	2.89M
Current Liabilities	-	64.51K	311.87K	399.55K	724.16K	1.18M	1.58M	3.13M	1.76M	5.25M	2.74M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	8.41K	0	0	154.92K
Total Equity	2.75M	2.83M	9.62M	6.92M	12.63M	15.69M	18.94M	10.09M	5.59M	55.04M	137.83M
Shares Outstanding	-	-	-	-	-	-	-	2.59M	2.98M	6.10M	6.69M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-1.19M	-2.63M	-2.68M	-3.02M	-4.66M	-	-7.23M	-7.86M	-6.40M	-12.20M
Investing Cash Flow	-	-	-	-	-	-	-4.92M	4.93M	-14.34M	-63.45M
Financing Cash Flow	1.26M	9.54M	-206.27K	9.35M	8.18M	-	32.87K	2.03M	59.29M	91.57M
Capital Expenditure	-	-	-	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-7.23M	-7.86M	-6.40M	-12.20M
Net Change in Cash	-	-	-	-	-	-	-12.11M	-903.32K	38.55M	15.92M
Share Buybacks	-	-	-	-	-	-	-	-	0	35.00M

Ratios (Annual)

Figures in %.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Net Margin %	-	-	-	-	-	-	-	-	-	-
ROE %	-41.9%	-172.1%	-46.7%	-33.5%	-40.2%	-	-104.2%	-150.4%	-28.3%	-10.0%
ROCE %	-42.1%	-172.6%	-48.1%	-34.2%	-41.5%	-	-104.3%	-158.0%	-29.4%	-12.1%

Shareholding Pattern

Insiders

23.23%

Institutions

93.27%

Public Float

121.50%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Janus Henderson Group PLC	19.67%	1.32M	$85.68M
2	RA Capital Management, L.P.	9.96%	667.21K	$43.40M
3	Saturn V Capital Management LP	5.16%	345.63K	$22.48M
4	Deerfield Management Company, L.P	4.83%	323.75K	$21.06M
5	Blackrock Inc.	4.73%	316.57K	$20.59M
6	Adage Capital Partners GP L.L.C.	4.62%	309.19K	$20.11M
7	Siren, L.L.C.	4.03%	270.12K	$17.57M
8	Adar1 Capital Management, LLC	3.95%	264.28K	$17.19M
9	Polar Capital Holdings PLC	3.38%	226.53K	$14.73M
10	Vanguard Capital Management LLC	3.26%	218.46K	$14.21M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MNPR

No recent headlines available.

MNPR · Healthcare